Alkermes (ALKS) Other Non Operating Income (2010 - 2026)
Alkermes' (ALKS) quarterly Other Non Operating Income came in at -$1.3 million in Q1 2026, down 183.1% year-on-year from $1.6 million in Q1 2025, and down 130.31% on a QoQ basis from $4.3 million in Q4 2025.
Alkermes (ALKS) Other Non Operating Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Other Non Operating Income data on file, last reported at -$1.3 million in Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 183.1% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 62.3% decrease from a year earlier, with the FY2025 full-year figure at $6.3 million, down 19.22% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$1.3 million, down from $4.3 million in the prior quarter.
- Over the last five years, Other Non Operating Income for ALKS reached as high as $5.4 million in Q4 2023 and fell as low as -$1.9 million in Q3 2022.
- Historically, Other Non Operating Income has averaged $1.1 million across 5 years, with a median of $558000.0 in 2024.
- On a YoY basis, Other Non Operating Income climbed as much as 915.32% in 2022 and fell as far as 746.18% in 2022.
- Year by year, Other Non Operating Income stood at -$1.9 million in 2022, then jumped by 388.92% to $5.4 million in 2023, then slipped by 6.5% to $5.0 million in 2024, then declined by 15.05% to $4.3 million in 2025, then plunged by 130.31% to -$1.3 million in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$1.3 million in Q1 2026, $4.3 million in Q4 2025, and -$280000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.29 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | -280,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 558,000.00 |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 5.37 Mn |
| Sep 30, 2023 | 149,000.00 |
| Jun 30, 2023 | -525,000.00 |
| Mar 31, 2023 | -39,000.00 |
| Dec 31, 2022 | -1.86 Mn |
| Sep 30, 2022 | -1.86 Mn |
| Jun 30, 2022 | 1.81 Mn |
| Mar 31, 2022 | 2.43 Mn |
| Dec 31, 2021 | 3.20 Mn |
| Sep 30, 2021 | 288,000.00 |
| Jun 30, 2021 | -222,000.00 |